WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

AI Overviews, which place generated answers directly at the top of search results, are improving the search experience for users. For businesses that rely on content to drive traffic from search ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...

Picture it: A marketing leader at a mid-sized financial services firm is finalizing next year's budget. Instead of spending days browsing multiple vendor websites, analyst PDFs, and peer reviews, she ...

Netflix launched its first major foray into broadcast-style reality competition programming on Tuesday night. Star Search, a reboot of the 1980s series, is the streamer’s attempt to finally crack the ...

An emotional advertisement released by World Without Exploitation featured various survivors of paedophile sex trafficker ...